| Recruiting | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer NCT05997615 | Vir Biotechnology, Inc. | Phase 1 |
| Unknown | Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer NCT03658434 | Zealand University Hospital | N/A |
| Completed | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) NCT03076203 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Active Not Recruiting | The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment NCT02955082 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Active Not Recruiting | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer NCT03016741 | Northwestern University | Phase 4 |
| Withdrawn | PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer NCT02867345 | Peking University | — |
| Unknown | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients NCT02691975 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer NCT02288936 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Unknown | Molecular Phenotype Changes and Personalized Treatment for CRPC NCT02208583 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Completed | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer NCT01631552 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer NCT01741116 | Korean Cancer Study Group | Phase 2 |
| Completed | Study of Weekly Cabazitaxel for Advanced Prostate Cancer NCT01518283 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Unknown | Radiotherapy vs Observation for CRPC NCT01590498 | Zhengzhou University | — |
| Completed | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prost NCT01487863 | Dendreon | Phase 2 |
| Completed | Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy NCT01422850 | CytoVac A/S | Phase 1 |
| Completed | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel NCT01260688 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy NCT01450683 | Stanford University | Phase 2 |
| Completed | Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer NCT01215799 | CytRx | Phase 2 |
| Terminated | TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) NCT01194960 | Oxford BioMedica | Phase 2 |
| Terminated | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as NCT01083615 | Achieve Life Sciences | Phase 3 |
| Terminated | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer NCT01020305 | Sandy Srinivas | Phase 1 / Phase 2 |
| Completed | Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer NCT00928252 | Queen's Medical Center | Phase 1 / Phase 2 |
| Terminated | RNActive®-Derived Therapeutic Vaccine NCT00906243 | University of Florida | Phase 1 / Phase 2 |
| Completed | Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy NCT00891345 | CytoVac A/S | Phase 1 |
| Unknown | Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer NCT00795171 | Medical University of Vienna | Phase 2 |
| Completed | A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer Wit NCT00699751 | Bayer | Phase 3 |
| Completed | Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-N NCT00636740 | Merrion Pharmaceuticals, LLC | Phase 2 |
| Completed | Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer NCT00583024 | David M Lubaroff | Phase 2 |
| Terminated | A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer NCT00525408 | Cadila Pharnmaceuticals | Phase 2 |
| Completed | A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men W NCT00571675 | Ascenta Therapeutics | Phase 2 |
| Completed | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer NCT00510718 | Pfizer | Phase 1 |
| Completed | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer NCT00570700 | University of California, Irvine | Phase 2 |
| Unknown | Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer P NCT00411853 | Sheba Medical Center | Phase 2 |
| Completed | A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patient NCT00675545 | National University Hospital, Singapore | Phase 2 |
| Completed | ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer NCT00477529 | Celgene | Phase 1 / Phase 2 |
| Completed | Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy NCT00407251 | British Columbia Cancer Agency | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy NCT00337077 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer NCT00448734 | Poniard Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone NCT00493766 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC NCT00313482 | Veeda Oncology | Phase 2 |
| Completed | Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer NCT00286091 | Amgen | Phase 3 |
| Completed | A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer NCT00286806 | Ascenta Therapeutics | Phase 1 / Phase 2 |
| Completed | RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer NCT00629525 | Daniel George, MD | Phase 2 |
| Completed | BAY88-8223, Does Response Study in HRPC Patients NCT00667199 | Bayer | Phase 2 |
| Unknown | Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemother NCT00133900 | Immunicon | — |
| Completed | Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy NCT00069745 | Agennix | Phase 3 |
| Completed | A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Ca NCT00156884 | Alberta Health services | Phase 2 |
| Completed | An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prosta NCT00201357 | National Health Research Institutes, Taiwan | Phase 2 |
| Completed | Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate NCT00151073 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate NCT01133704 | Dendreon | Phase 3 |
| Completed | Study Evaluating the Safety and Tolerability of L-377202 NCT00987753 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Terminated | YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Respon NCT00048659 | Astellas Pharma Inc | Phase 2 |
| Completed | Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel NCT00082134 | Genzyme, a Sanofi Company | Phase 2 |